臨床検査68巻6号

2024年06月発行

今月の特集 免疫・アレルギー性肺疾患と検査 疾患各論

COVID-19と免疫・アレルギー性肺疾患（喘息・間質性肺炎）の関係

著者： 竹下裕理¹ 長瀬洋之¹

所属機関： ¹帝京大学医学部内科学講座呼吸器・アレルギー学

ページ範囲：P.742 - P.747

Point

●新型コロナウイルス感染症（COVID-19）流行期に喘息の増悪は減少した．マスク装着などによる呼吸器感染症の減少が関与した可能性がある．

●喘息における2型炎症や，吸入ステロイド薬（ICS）は，ウイルス侵入受容体であるアンジオテンシン変換酵素（ACE）2発現を低下させる．

●喘息患者はCOVID-19に罹患しにくい傾向があり重症化リスクも高くない．

●一方，間質性肺疾患（ILD）患者がCOVID-19に罹患した際の予後は不良である．

●COVID-19は膠原病肺を含めた自己免疫疾患を誘発する可能性がある．

参考文献

1）Nagase H, Nishimura Y, Matsumoto H, et al：The prevalence of comorbid respiratory disease among COVID-19 patients, and mortality during the first wave in Japan: A nationwide survey by the Japanese Respiratory Society. Respir Investig　59：679-682，2021

2）Williamson EJ, Walker AJ, Bhaskaran K, et al：Factors associated with COVID-19-related death using OpenSAFELY. Nature　584：430-436，2020

3）Peters MC, Sajuthi S, Deford P, et al：COVID-19-related Genes in Sputum Cells in Asthma. Relationship to Demographic Features and Corticosteroids. Am J Respir Crit Care Med　202：83-90，2020

4）Kimura H, Francisco D, Conway M, et al：Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. J Allergy Clin Immunol　146：80-88.e8，2020

5）Schultze A, Walker AJ, MacKenna B, et al：Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med　8：1106-1120，2020

6）Bloom CI, Drake TM, Docherty AB, et al：Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir Med　9：699-711，2021

7）Baker JR, Mahdi M, Nicolau DV Jr, et al：Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis. Lancet Respir Med　10：545-556，2022

8）Ramakrishnan S, Nicolau DV Jr, Langford B, et al：Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med　9：763-772，2021

9）Yu LM, Bafadhel M, Dorward J, et al：Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet　398：843-855，2021

10）Kitazawa H, Hizawa N, Nishimura Y, et al：The impact of the COVID-19 pandemic on asthma treatment in Japan: Perspectives based on doctors' views. Respir Investig　59：670-674，2021

11）Kondoh Y, Kataoka K, Ando M, et al：COVID-19 and acute exacerbation of interstitial lung disease. Respir Investig　59：675-678，2021

12）Wang Y, Jin C, Wu CC, et al：Organizing pneumonia of COVID-19: Time-dependent evolution and outcome in CT findings. PLoS One　15：e0240347，2020

13）藤原清宏：軽症で自宅・ホテル療養とされ，隔離解除後に症状持続ないし悪化を来しCOVID肺炎を認め，ステロイド治療により改善した2症例．呼吸臨床　5：e00135，2021

14）Liu Y, Sawalha AH, Lu Q：COVID-19 and autoimmune diseases. Curr Opin Rheumatol　33：155-162，2021

15）Alosaimi B, Mubarak A, Hamed ME, et al：Complement Anaphylatoxins and Inflammatory Cytokines as Prognostic Markers for COVID-19 Severity and In-Hospital Mortality. Front Immunol　12：668725，2021

16）Lingel H, Meltendorf S, Billing U, et al：Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals. J Autoimmun　122：102682，2021

17）Shimizu H, Matsumoto H, Sasajima T, et al：New-onset dermatomyositis following COVID-19: A case report. Front Immunol　13：1002329，2022

18）Dotan A, Muller S, Kanduc D, et al：The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev　20：102792，2021

19）Gagiannis D, Steinestel J, Hackenbroch C, et al：Clinical, Serological, and Histopathological Similarities Between Severe COVID-19 and Acute Exacerbation of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD). Front Immunol　11：587517，2020